论文部分内容阅读
目的：系统评价XELOX和FOLFOX方案在治疗晚期胃癌的疗效。方法利用meta分析的方法综合评价国内公开发表的所有关于ELOX和FOLFOX方案治疗晚期胃癌的随机和非随机对照试验。最终符合选入标准的文献11篇,包含734例患者,其中ELOX组364例,FOLFOX组370例。评价指标：实体瘤疗效,毒副反应。结果与FOLFOX治疗组相比,XELOX组手足综合征的发生率较高(OR为5.09,95%置信区间为3.19~8.11)。两组在治疗效果,其它相关毒副作用方面,其差异均无统计学意义(＞0.05)。结论 META分析结果显示：XELOX方案在晚期胃癌治疗方面的疗效并不优于FOLFOX方案,且在某些毒副作用的发生率高于FOLFOX方案。“,”Objective To evaluate the ef icacy of XELOX versus FOLFOX in the treatment of advanced gastric cancer by Meta-analysis. Methods Synthetical y assessed the literatures al about ef icacy of EIDOX versus FOLFOX in the treatment of advanced gastric cancer by meta analysis in China. Final y, 11 literatures including 734 patients were according with standard. Among them 364 patients in ELOX group and 370 patients in FOLFOX group. The evaluation parameters included Curative ef ect of Solid tumor and Adverse reaction. Results The frequency of Hand and foot syndrome was higher in the XELOX group than that in the FOLFOX group(OR:5.09,95%CI:3.19~8.11,P<0.05);There were no significant dif erences in Adverse reactions( ﹥0.05).Conclusion Meta analysis showed that XELOX have no specific advantage in the ef icacy in the treatment of advanced gastric cancer while it elevated incidence of Hand and foot syndrome. Because in the methodological quality is low and the amount is less, We looking forward to more high quality of randomized control ed trials to provide a bet er quality of evidence.